



Swansea University
Prifysgol Abertawe



Cronfa - Swansea University Open Access Repository

This is an author produced version of a paper published in:

Malaria Journal

Cronfa URL for this paper:

<http://cronfa.swan.ac.uk/Record/cronfa40380>

Paper:

Phok, S. & Lek, D. (2017). Evidence on anti-malarial and diagnostic markets in Cambodia to guide malaria elimination strategies and policies. *Malaria Journal*, 16(1)

<http://dx.doi.org/10.1186/s12936-017-1807-y>

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>)

This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior permission for personal research or study, educational or non-commercial purposes only. The copyright for any work remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium without the formal permission of the copyright holder.

Permission for multiple reproductions should be obtained from the original author.

Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the repository.

<http://www.swansea.ac.uk/library/researchsupport/ris-support/>



Evidence on anti-malarial and diagnostic markets in Cambodia to guide malaria elimination strategies and policies

ACTwatch Group *et al.*

RESEARCH

Open Access



Evidence on anti-malarial and diagnostic markets in Cambodia to guide malaria elimination strategies and policies

ACTwatch Group^{1*}, Sochea Phok^{2*} and Dysoley Lek^{3,4}

Abstract

Background: Understanding Cambodia's anti-malarial and diagnostic landscape in 2015 is critical for informing and monitoring strategies and policies as Cambodia moves forward with national efforts to eliminate malaria. The aim of this paper is to present timely and key findings on the public and private sector anti-malarial and diagnostic landscape in Cambodia. This evidence can serve as a baseline benchmark for guiding implementation of national strategies as well as other regional initiatives to address malaria elimination activities.

Methods: From August 17th to October 1st, 2015, a cross sectional, nationally-representative malaria outlet survey was conducted in Cambodia. A census of all public and private outlets with potential to distribute malaria testing and/or treatment was conducted among 180 communes. An audit was completed for all anti-malarials, malaria rapid diagnostic tests (RDT) and microscopy.

Results: A total of 26,664 outlets were screened, and 1303 outlets were eligible and interviewed. Among all screened outlets in the public sector, 75.9% of public health facilities and 67.7% of community health workers stocked both malaria diagnostic testing and a first-line artemisinin-based combination therapy (ACT). Among anti-malarial-stocking private sector outlets, 64.7% had malaria blood testing available, and 70.9% were stocking a first-line ACT. Market share data illustrate that most of the anti-malarials were sold or distributed through the private sector (58.4%), including itinerant drug vendors (23.4%). First-line ACT accounted for the majority of the market share across the public and private sectors (90.3%). Among private sector outlets stocking any anti-malarial, the proportion of outlets with a first-line ACT or RDT was higher among outlets that had reportedly received one or more forms of 'support' (e.g. reportedly received training in the previous year on malaria diagnosis [RDT and/or microscopy] and/or the national treatment guidelines for malaria) compared to outlets that did not report receiving any support (ACT: 82.1 and 60.6%, respectively; RDT: 78.2 and 64.0%, respectively).

Conclusion: The results point to high availability and distribution of first-line ACT and widespread availability of malaria diagnosis, especially in the public sector. This suggests that there is a strong foundation for achieving elimination goals in Cambodia. However, key gaps in terms of availability of malaria commodities for case management must be addressed, particularly in the private sector where most people seek treatment. Continued engagement with the private sector will be important to ensure accelerated progress towards malaria elimination.

Keywords: Malaria elimination, Case management, Anti-malarial, ACT, Private sector, Cambodia

*Correspondence: mlittrell@psi.org; psochea@psk.org.kh

¹ Population Services International, 1120 19th St NW, Suite 600, Washington, DC 20036, USA

² PSI Cambodia (PSK), No. 29, Street 334, Boeung Keng Kang I, Chamcar Mon, Phnom Penh, Kingdom of Cambodia

Full list of author information is available at the end of the article

Background

Over the past decade, malaria interventions have made substantial progress in Cambodia, demonstrated by rapid declines in the malaria burden since the early 2000s, with reported cases decreasing by approximately 50% between 2004 and 2014 [1]. However, of Cambodia's 25 provinces, 21 are still considered to be endemic, and an estimated 48% of the population live in high transmission areas [2]. Furthermore, there has been a resurgence of malaria cases between 2014 and 2015, from 44,748 to 56,371, and resistance to artemisinin-based combination therapy (ACT) continues to threaten progress towards national malaria strategies [3]. This situation is all the more pressing given the country's recent commitment to eliminate malaria by 2020, as coverage of appropriate case management in the context of malaria elimination strategies will be critical to achieving this goal [1].

In 2016, Cambodia's National Centre for Parasitology, Entomology and Malaria Control (CNM) released the Malaria Elimination Action Framework, 2016–2020, (MEAF) outlining the country's strategies and plans to achieve elimination of *Plasmodium falciparum* and multi-drug resistant malaria by 2020 [1]. Several key objectives are described in the MEAF, including 100% parasitological diagnosis for all suspected cases and effective, efficacious treatment of all confirmed uncomplicated malaria cases using first-line ACT: dihydroartemisinin-piperaquine (DHA PPQ) or artesunate-mefloquine (ASMQ) fixed-dose combination (FDC). For *P. falciparum* infections or mixed infections that include *P. falciparum*, the MEAF stipulates use of a single low-dose of primaquine. For *P. vivax* infections, a standard dose of primaquine for up to 14 days is indicated in order to prevent relapse. The MEAF stipulates that glucose-6-phosphate dehydrogenase (G6PD) testing should be conducted prior to administering primaquine treatment for *Plasmodium vivax* cases.

The MEAF also outlines several key strategies to ensure readiness of public and private facilities to adhere to the national treatment guidelines for malaria [1]. Malaria treatment or referral services will be available at all public health facilities, licensed private sector providers, trained village malaria workers (VMW), mobile malaria workers, and military medical services. In the public sector, the VMW programme, which provides malaria diagnosis and treatment among remote communities through a community-based health workforce, will be scaled up. The number of villages with at least one VMW will almost double, from 2539 currently to 4528 over the course of the next 5 years. In addition, these community-based providers will be allowed to administer low dose primaquine for *P. falciparum* to reduce malaria transmission and for radical cure of *P. vivax*. The VMW will

also receive training on malaria, case management, counseling, and health education.

In the private sector, where most patients in Cambodia seek treatment [4], the strategy outlines the scale-up of the existing public–private mix (PPM) programme by mapping all existing providers and registering new providers. Refresher courses on early malaria diagnosis, treatment, referral, and reporting will be conducted every 2 years for PPM programme providers. The strategy also specifies that providers that do not qualify for the PPM programme will not be allowed to provide or sell anti-malarials or diagnostics. However, efforts will also be made to identify and select unlicensed private providers that can be targeted for licensing so that they can be registered under the PPM programme. Several initiatives will be implemented to enforce the regulation of private sector service providers through the Department of Drug and Food (DEF) and the Anti-Economic Crime Police. Finally, the strategy also stipulates that there will be increased efforts to ban the import and sale of anti-malarial drugs that are not in the national malaria treatment guidelines [1]. This will be implemented by keeping the DDF updated on the anti-malarial drugs that are not included in the national malaria treatment guidelines.

These current national strategies outlined in the MEAF build on the country's earlier efforts to promote expansion of the public sector and increased regulation of the private sector [5, 6]. In the public sector, the VMW programme has been a key strategy for increasing access to malaria commodities among remote rural populations. By 2014, a decade after it was piloted in 300 villages, the VMW programme covered over 1600 villages and 130 mobile communities across 17 malaria endemic provinces [1]. Private sector engagement has been in place since 2002, through national distribution of subsidized anti-malarials and rapid diagnostic testing (RDT) for private sector providers across the country [6]. In 2008, oral artemisinin monotherapy was banned, with several hard-line strategies in place to enforce the policy [7]. Increased regulation of the private sector commenced around this time, to reduce the role of unauthorized private sector providers, including drug stores and general retailers, in anti-malarial distribution, while continuing to support distribution by registered private for-profit health facilities and pharmacies. In 2011, the CNM and the Ministry of Health (MoH) established the aforementioned PPM programme to further engage the private sector and provided subsidized commodities, training, and supervision. The PPM programme was subsequently scaled up in 2014, with nearly 1200 licensed private providers enrolled across 34 operational districts (ODs) out of a total of 45 malaria endemic ODs [1]. Indeed, efforts to date by the CNM and other implementing partners have been highly

successful in strengthening and shaping Cambodia's anti-malarial and malaria diagnostic landscape. Supply-side evidence from 2013 has shown an increase in the widespread distribution of first-line ACT, successful removal of oral artemisinin monotherapy, a decrease in the number of unregulated outlets stocking anti-malarials, and an increase in public sector anti-malarial market share and composition, namely through the VMW programme [5].

Evidence on the role and performance of the public and private sectors will provide a baseline benchmark for guiding implementation of national strategies. The ACTwatch project, implemented since 2008 across a number of countries by Population Services International (PSI), provides timely, relevant, and high quality anti-malarial market evidence to inform and monitor national and global policy, strategy, and funding decisions for improving malaria case management [8, 9]. In 2015, an ACTwatch survey was implemented in Cambodia. The evidence generated from this project provides an opportunity to present contemporary market intelligence data on Cambodia's anti-malarial and diagnostic landscape as a means to inform and monitor strategies and policies as the country moves forward with elimination activities. The evidence from this survey can also help to frame the anti-malarial and diagnostic market in the context of the MEAF strategies, as well as other regional and country-specific initiatives to accelerate progress towards elimination of malaria. The objectives of this paper are twofold: (1) to describe contemporary public and private sector readiness (availability of malaria commodities) and performance (market share) for malaria case management; and (2) to compare private sector readiness and provider knowledge between outlets that reportedly received

supportive interventions (e.g. access to malaria commodities, or training) with private outlets that did not receive these interventions.

Methods

Design and sampling

The study population was defined as all outlets with the 'potential' to sell or distribute anti-malarial medicines and/or provide malaria blood testing. The methodology of ACTwatch adopts a more inclusive, rather than exclusive, way of determining outlet types for the study, by including a broad list of outlet types that may or may not sell or distribute anti-malarial medicines and/or provide malaria blood testing. While some outlets are expected to have anti-malarials, other outlets, such as general retailers, may be theorized to not stock these medicines. Such outlets are, however, included in the sample as a means to investigate this theory and to determine if these outlets do indeed contribute to malaria case management in a given country. Outlet types that are included in the sample are determined according to each specific country context. The outlet types that were included in the Cambodia survey are described in Table 1. Outlets that did not serve the general public (e.g. military facilities) were excluded from the outlet survey, but military and police facilities that also served the general public were included.

In 2014, the World Health Organization (WHO) used available evidence about artemisinin resistance to define a 3-tier stratification system for targeting action to address drug resistance [10]. This tier system replaced the previous zone stratification used in Cambodia [11]. Areas designated as Tier 1 were prioritized for immediate

Table 1 Outlet types and definitions

| Sector and facility type | Definition |
|--------------------------------------|--|
| Public sector | |
| Public health facilities | Referral hospitals, health centers, former district hospitals, health posts, NGO/mission/faith-based hospitals, NGO/mission/faith-based clinics, and NGO/mission/faith-based diagnostic laboratories |
| Community health workers | Community-based volunteers, either Village Malaria Workers, Mobile Malaria Workers, or Plantation Malaria Workers, who are equipped with anti-malarial treatment and malaria blood testing |
| Private sector | |
| Private for-profit health facilities | Private hospitals, clinics, polyclinics, cabinets, health care rooms, and private diagnostic laboratories and would be expected to have been registered in country |
| Pharmacies | Regulated by a national regulatory authority and staffed by pharmacists or qualified health practitioners. These include pharmacies, clinical pharmacies, depot A, and depot B. These may or may not be licensed by a national regulatory authority |
| Drug stores | Drug stalls in rural markets or shops that primarily sell medicines. These outlets are not guaranteed to be staffed by qualified health dispensers or practitioners and are not typically licensed by a national regulatory authority |
| General retailers | Grocery stores and village shops and are not licensed by a national regulatory authority |
| Itinerant drug vendors | Mobile providers found primarily in rural areas, typically working within a radius of their home. They are not registered with any national regulatory authority. Some itinerant drug vendors operate with both a fixed location and a mobile service, while others operate solely through a mobile service. |

multifaceted response to contain or eliminate resistance. Areas designated as Tier 2 were prioritized for intensified malaria control to reduce transmission and/or limit the risk of emergence or spread of resistant parasites. Tier 3 areas had no evidence of artemisinin resistance and limited contact with Tier 1 areas. Malaria control in these areas focused on vector control, increasing coverage with confirmatory testing and treatment with quality-assured ACT [12]. The Cambodia outlet survey was stratified to deliver estimates for domains according to this tier stratification system, with the first research domain designated as tier 1 provinces and the second research domain designated as tier 2 provinces.

From a list of all communes in each research domain, the required number of units was selected with probability proportional to size (PPS). Selection of units with PPS was completed based on population estimates obtained from a 2010 Ministry of Planning projection based on findings from the 2008 national census. The sampling frames for each tier excluded communes that were located in non-malaria-endemic areas according to information provided by the CNM.

Within each commune, a census of all outlets with the potential to sell or distribute anti-malarials and/or provide malaria blood testing was conducted. Outlets were eligible for a provider interview and malaria product audit if they met at least one of three study criteria: (1) one or more anti-malarials reportedly in stock on the day of the survey; (2) one or more anti-malarials reportedly in stock within the three months preceding the survey; and/or (3) malaria RDT in stock or malaria microscopy available on the day of the survey.

Sample size

Sample size was determined to estimate with precision ($\pm 10\%$ points) two key indicators among public and private outlets: (1) proportion of outlets with first-line anti-malarial treatments available, among outlets with anti-malarial(s) in stock on the day of the survey; and (2) proportion of outlets with malaria blood testing (RDT or microscopy) available, among outlets with anti-malarial(s) in stock on the day of the survey or within the past 3 months. Estimates from the 2013 ACTwatch outlet survey were used to complete these calculations. A sample size of 80 Tier 1 and 80 Tier 2 communes was anticipated to yield the minimum required numbers of outlets.

Data collection

Standard procedures used by the ACTwatch project to implement surveys have been described elsewhere [27]. Interviewers, supervisors, and quality controllers received training that included an orientation to the study and questionnaire, classroom training on completing

anti-malarial and RDT audits, and a field exercise. Following training, data collection was implemented from August 17th to October 1st, 2015. The outlet survey was conducted using handheld devices with an Android operating system and electronic forms created using DroidDB (SYWARE, Inc., Cambridge, MA, USA). The questionnaire was translated from English to Khmer, and translated back into English to resolve any discrepancies prior to the survey implementation.

A series of screening questions were administered at all outlets to determine eligibility for the survey. Outlets where anti-malarial medicines were reportedly sold and/or malaria blood testing was reportedly available were invited to participate in the survey. Following informed consent procedures, an audit of all available anti-malarial medicines and RDT was conducted. In addition to the product audit, a series of questions was administered to the senior-most provider regarding malaria case management knowledge and practices as well as provider training and qualifications and reporting on malaria caseload data. Up to three visits were made to all outlets to complete the screening process, audit, and provider interview as needed.

Data analysis

Electronic data were imported to a master dataset using Microsoft Access (Microsoft Corporation, Redmond, Washington, USA), and records were triangulated with questionnaires, field supervisor tracking records, and daily activity logs completed by interviewers. All data cleaning and analysis was completed using Stata 12.1 (StataCorp, College Station, TX, USA). Sampling weights were applied to account for variations in probability of selection, and standard error estimation accounted for clustering at the commune level.

Indicators were produced according to ACTwatch standards that have been implemented across time and country studies and which have been described in detail elsewhere [8, 9]. Availability of any anti-malarial was calculated with a denominator of all screened outlets. In the public sector, the availability of specific types of anti-malarials was calculated using the denominator of all screened outlets, given that anti-malarials should be available at all public health facilities and community health workers (CHW) designated as VMW. Availability of specific anti-malarial categories in the private sector was calculated using a denominator of private sector outlets stocking any anti-malarial.

The volumes of each anti-malarial that were reportedly distributed in the week prior to the survey, according to provider reports, were standardized into adult equivalent treatment doses (AETD) to allow for comparisons between medicines, based on WHO treatment

guidelines for the amount of active ingredient required to treat an adult weighing 60 kg [13]. These standardized AETD volumes were then used to calculate market share for each anti-malarial category. Audited medicines that were missing information required to calculate AETD (strength or amount distributed) were excluded from this indicator.

Private sector outlet support status (the presence or absence of support) was calculated according to multiple provider self-reported variables. An outlet was considered as having received any support if the provider reported one or more of the following: (1) outlet received subsidized anti-malarials and/or malaria RDT; (2) at least one provider at the outlet received training on the national treatment guidelines for malaria or malaria diagnosis within the previous year; (3) outlet received a supervisory/regulatory visit within the previous year; and/or (4) outlet reports malaria caseload data to the government or a non-governmental organization. Support status was very likely to be correlated with outlet type, given that governmental and non-governmental organizations target only registered private health facilities and pharmacies for support and do not typically support unauthorized drug stores, general retail outlets, or itinerant drug vendors. Availability and provider knowledge indicators for supported and non-supported outlets were therefore adjusted for outlet type using logistic regression to produce adjusted predicted probabilities. Anti-malarial availability indicators were calculated among outlets with any anti-malarial in stock on the day of the survey. Malaria blood testing availability and provider knowledge of first-line treatment indicators were calculated among outlets with any anti-malarial in stock on the day of the survey or within the three months prior to the survey.

Results

Sample description

A total of 26,664 outlets were screened to assess eligibility for the outlet survey, and only 51 outlets refused screening or survey participation. Of the outlets screened, 604 (2.3%) were in the public sector, and 26,060 (97.7%) were in the private sector. A total of 1303 outlets were eligible and interviewed, and only five outlets met eligibility criteria but did not complete the interview. Of the eligible outlets, 557 (42.7%) were in the public sector, and 746 (57.3%) were in the private sector.

Of the 1303 outlets interviewed, 858 (65.8%) were stocking at least one anti-malarial on the day of the survey, 1112 (85.3%) were stocking at least one anti-malarial either on the day of the survey or within the previous three months, and 191 (14.7%) were stocking a malaria diagnostic test (either RDT or microscopy) but did not

stock anti-malarial medicines on the day of the survey or within the previous three months.

In total, 164 outlets reported distributing an anti-malarial during the week prior to the survey, and 427 outlets reported providing or distributing a malaria diagnostic test in the week prior to the survey. Table 2 shows a detailed breakdown of the screening, eligibility, and interview results across outlet types and sectors. Provider characteristics are included in Additional file 1.

Availability in the public sector

Table 3 shows a detailed breakdown of malaria blood testing availability, first-line anti-malarial availability, and readiness for malaria case management across screened public sector outlets. Availability of malaria diagnostics was relatively high in the public sector, with 85.9% of all public sector outlets stocking either malaria RDT or microscopy, and this was highest among CHW (87.2%). Availability of malaria RDT was higher than microscopy, with 85.8% of public sector outlets stocking malaria RDT and only 7.2% reporting availability of malaria microscopy. Malaria microscopy was available in only 27.8% of public health facilities.

Availability of first-line ACT in the public sector was slightly lower than diagnostic availability, with just under three-fourths of all public sector outlets (74.7%) stocking any first-line ACT on the day of the survey. Among these outlets, 100% of the first-line ACT audited was DHA PPQ, as no outlets were stocking ASMQ FDC. Primaquine was not available in any public sector outlets.

Three-fourths of public health facilities (75.9%) had both malaria diagnostic testing and a first-line ACT. Malaria case management readiness was lower among CHW, with only 67.7% of CHW stocking both malaria testing and first-line treatment.

Availability in the private sector

Table 4 shows a detailed breakdown of availability of any anti-malarial among all private sector outlets, followed by availability of malaria blood testing and anti-malarials among anti-malarial-stocking private sector outlets.

Approximately one-third of screened private for-profit health facilities (31.0%), one-fifth of pharmacies (20.5%), and 15.1% of itinerant drug vendors were stocking any anti-malarial on the day of the survey. Of 23,840 general retailers screened, only 0.2% were found to be stocking any anti-malarial.

Among anti-malarial-stocking private sector outlets, nearly two-thirds had malaria blood testing available (64.7%); 63.8% were stocking a malaria RDT, while 8.7% had malaria microscopy available. Availability of malaria blood testing was highest in private for-profit health facilities (83.0%) and pharmacies (70.1%). Over half of

Table 2 Outlet survey sample

| | Public health facility | Community health workers | Private not-for-profit facility | All public sector | Private for-profit health facility | Pharmacy | Drug store | General retailer | Itinerant drug vendor | All private sector | All outlets |
|---|------------------------|--------------------------|---------------------------------|-------------------|------------------------------------|----------|------------|------------------|-----------------------|--------------------|-------------|
| Number of outlets | | | | | | | | | | | |
| Screened | 173 | 430 | 1 | 604 | 668 | 290 | 338 | 23,840 | 924 | 26,060 | 26,664 |
| Eligible and interviewed | 142 | 415 | 0 | 557 | 327 | 99 | 46 | 39 | 235 | 746 | 1303 |
| Refused | 1 | 0 | 0 | 1 | 2 | 1 | 1 | 43 | 3 | 50 | 51 |
| Eligible but not interviewed (interview non-participation) | 0 | 1 | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 4 | 5 |
| Number of interviewed outlets | | | | | | | | | | | |
| With at least one anti-malarial | 137 | 330 | n/a | 467 | 186 | 45 | 22 | 29 | 109 | 391 | 858 |
| With at least one anti-malarial, or at least one anti-malarial in the past 3 months | 140 | 402 | n/a | 542 | 237 | 74 | 34 | 39 | 186 | 570 | 1112 |
| With malaria blood testing, but no anti-malarials in stock on the day of the survey or in the previous 3 months | 2 | 13 | n/a | 15 | 90 | 25 | 12 | 0 | 49 | 176 | 191 |

Table 3 Availability of malaria commodities and readiness for case management in the public sector, among all screened outlets

| | Public health facility N = 173 % (95% CI) | Community health workers N = 430 % (95% CI) | All public sector N = 603 % (95% CI) |
|---|---|---|--|
| Diagnostics | | | |
| Any malaria blood testing | 82.3 (74.9, 87.8) | 87.2 (82.7, 90.6) | 85.9 (82.1, 89.0) |
| Malaria microscopy | 27.8 (21.0, 35.8) | 0.3 (0.1, 1.8) | 7.2 (5.3, 9.7) |
| RDT | 81.7 (74.3, 87.4) | 87.2 (82.7, 90.6) | 85.8 (81.9, 88.9) |
| Anti-malarials | | | |
| Any first-line ACT (DHA PPQ and/or ASMQ FDC) | 76.5 (67.8, 83.5) | 74.1 (66.2, 80.7) | 74.7 (68.3, 80.1) |
| DHA PPQ | 76.5 (67.8, 83.5) | 74.1 (66.2, 80.7) | 74.7 (68.3, 80.1) |
| ASMQ FDC | 0.0 (-) | 0.0 (-) | 0.0 (-) |
| Primaquine | 0.0 (-) | 0.0 (-) | 0.0 (-) |
| Other non-artemisinin therapy | 8.9 (4.9, 15.5) | 0.0 (-) | 2.2 (1.3, 3.9) |
| IV/IM artesunate | 0.0 (-) | n/a | 0.0 (-) |
| Readiness | | | |
| Availability of first-line ACT and malaria blood testing | 75.9 (67.1, 82.9) | 67.7 (60.2, 74.3) | 69.7 (63.6, 75.1) |
| Availability of first-line ACT, blood testing not available | 0.7 (0.2, 2.4) | 6.4 (4.1, 9.9) | 5.0 (3.2, 7.6) |

itinerant drug vendors were stocking a diagnostic test (60.4%).

Among those private sector outlets stocking any anti-malarial, 70.9% were stocking a first-line ACT, all of which was DHA PPQ rather than ASMQ FDC. Private for-profit health facilities and pharmacies had the highest availability of a first-line ACT (90.0 and 85.6%, respectively). Availability of a first-line ACT was also moderately high among anti-malarial-stocking itinerant drug vendors (62.8%). Fewer than half of anti-malarial-stocking drug stores (47.9%) and only 2.8% of anti-malarial-stocking general retailers had a first-line ACT available. Chloroquine was most commonly available among drug stores (20.5%), general retailers (67.1%), and itinerant drug vendors (30.7%). Only one package of oral AMT was found, and this product was audited at a general retail outlet.

Market share

Figure 1 shows a detailed breakdown of the anti-malarial market share across sectors, outlet types, and anti-malarial type. Most of the anti-malarials were sold or distributed through the private sector (58.4%). Across the private sector, most of the anti-malarial market share was composed of private for-profit health facilities (26.7%) and itinerant drug vendors (23.4%).

In terms of the types of anti-malarials being sold or distributed, DHA PPQ contributed to the majority of the market share in both the public and private sectors (90.3% of the national market share). The private sector

anti-malarial market share was also composed of chloroquine (4.9%), which was primarily distributed through private for-profit health facilities, general retailers, and itinerant drug vendors.

Figure 2 shows a detailed breakdown of the diagnostic market share across sectors, outlet types, and diagnostic test type. The majority of the diagnostic market share was composed of the private sector (57.6%), with most diagnostic tests provided through private for-profit health facilities (37.9%), itinerant drug vendors (9.1%), and pharmacies (8.6%). Most diagnostic testing was performed using RDT rather than microscopy.

Private sector support

Table 5 shows a detailed breakdown of support reportedly received across private sector outlet types. Nearly half of all interviewed outlets (44.4%) reported having received any type of support. Nearly two-thirds of private for-profit health facilities (60.2%) and nearly three-fourths of pharmacies (71.7%) reported having received any type of support, while one in four itinerant drug vendors (25.5%) reported receiving any type of support.

Among outlets that reported receiving support, the most common types of support reportedly received were access to subsidized RDT (63.0%), training in the past year on malaria diagnosis or the national treatment guidelines for malaria (59.1%), and access to subsidized anti-malarials (57.5%). Only 21.4% reported receiving a supervisory or regulatory visit within the past year, and 36.9% reported keeping and reporting malaria caseload

Table 4 Availability of malaria commodities in the private sector



| | Private for-profit health facility % (95% CI) | Pharmacy % (95% CI) | Drug store % (95% CI) | General retailer % (95% CI) | Itinerant drug vendor % (95% CI) | All private sector % (95% CI) |
|---|--|------------------------|--------------------------|--------------------------------|-------------------------------------|----------------------------------|
| Among all screened outlets, availability of | N = 668 | N = 290 | N = 338 | N = 23,840 | N = 924 | N = 26,060 |
| Any anti-malarial | 31.0 (26.1, 36.3) | 20.5 (14.8, 27.6) | 6.6 (4.2, 10.1) | 0.2 (0.1, 0.4) | 15.1 (11.4, 19.8) | 1.8 (1.5, 2.1) |
| Among anti-malarial-stocking outlets or outlets stocking anti-malarials in the past 3 months, availability of | N = 237 | N = 74 | N = 34 | N = 39 | N = 186 | N = 570 |
| Diagnostics | | | | | | |
| Any malaria blood testing | 83.0 (76.8, 87.8) | 70.1 (58.2, 79.7) | 60.9 (40.8, 77.9) | 0.0 (-) | 60.4 (50.6, 69.4) | 64.7 (58.5, 70.3) |
| Malaria microscopy | 15.6 (10.9, 22.0) | 4.8 (1.6, 13.1) | 4.0 (0.6, 21.7) | 0.0 (-) | 5.6 (3.2, 9.8) | 8.7 (6.4, 11.9) |
| RDT | 81.3 (74.8, 86.5) | 70.1 (58.2, 79.7) | 60.9 (40.8, 77.9) | 0.0 (-) | 59.8 (50.0, 68.9) | 63.8 (57.6, 69.6) |
| Among anti-malarial stocking outlets, availability of | N = 186 | N = 45 | N = 22 | N = 29 | N = 109 | N = 391 |
| Anti-malarials | | | | | | |
| Any first-line ACT | 90.0 (82.5, 94.5) | 85.6 (74.3, 92.4) | 47.9 (27.8, 68.6) | 2.8 (0.5, 15.6) | 62.8 (51.7, 72.7) | 70.9 (63.1, 77.6) |
| DHA PPQ | 90.0 (82.5, 94.5) | 85.6 (74.3, 92.4) | 47.9 (27.8, 68.6) | 2.8 (0.5, 15.6) | 62.8 (51.7, 72.7) | 70.9 (63.1, 77.6) |
| ASMQ FDC | 0.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) |
| Primaquine | 0.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) |
| Chloroquine | 4.6 (2.0, 10.3) | 7.7 (2.9, 19.1) | 20.5 (9.7, 38.1) | 67.1 (27.6, 91.6) | 30.7 (20.1, 43.7) | 19.7 (14.1, 26.9) |
| Other non-artemisinin therapy | 1.3 (0.3, 5.4) | 0.0 (-) | 6.8 (1.9, 21.4) | 0.0 (-) | 1.8 (0.6, 5.2) | 1.5 (0.7, 3.3) |
| Oral AMT | 0.0 (-) | 0.0 (-) | 0.0 (-) | 2.3 (0.4, 12.7) | 0.0 (-) | 0.2 (0.0, 1.2) |
| IV/IM artesunate | 0.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) | 0.7 (0.1, 4.0) | 0.2 (0.0, 1.3) |
| Availability of first-line ACT and malaria blood testing | 80.4 (72.6, 86.3) | 67.1 (52.5, 79.0) | 23.6 (10.0, 46.1) | 0.0 (-) | 50.8 (40.2, 61.3) | 59.4 (51.9, 66.6) |
| Availability of first-line ACT, blood testing not available | 9.6 (6.1, 15.0) | 18.5 (10.5, 30.5) | 24.3 (9.4, 49.9) | 2.8 (0.5, 15.6) | 12.0 (7.0, 19.9) | 11.5 (8.4, 15.4) |

data to either the government or a non-governmental organization.

Figure 3 shows several key indicators showing anti-malarial and diagnostic market availability, and provider knowledge, according to outlet support status (the presence or absence of private sector support), while controlling for outlet type. Among private sector outlets stocking any anti-malarial, the proportion of outlets with a first-line ACT was higher among outlets that had reportedly received any type of support or engagement (hereinafter referred to as 'supported' outlets) compared to outlets that did not report receiving any support (82.1 and 60.6%, respectively). Similar results were observed for availability of malaria blood testing, where 78.2% of supported

outlets had a malaria blood test available compared to 64.0% of unsupported outlets. With regards to provider knowledge, 80.2% of providers in supported outlets correctly stated the first-line treatment for uncomplicated malaria (either DHA PPQ or ASMQ FDC) compared to just 47.0% of providers in unsupported outlets. Finally, supported outlets were less likely to be stocking an anti-malarial not indicated in the national treatment guidelines for malaria compared to unsupported outlets (14.0% compared to 43.0%, respectively).

Figure 4 shows median prices for malaria RDT and DHA PPQ according to outlet support. Outlets that reported having received any type of support reported a median consumer price of \$0.75 for a malaria RDT



compared to a median price of \$1.49 in unsupported outlets. Similarly, the median price of one AETD of DHA PPQ in supported outlets was \$1.24 compared to \$2.49 in unsupported outlets.

Discussion

The 2015 outlet survey findings provide contemporary evidence on the availability and market share of malaria commodities. Several positive outlet survey findings regarding the readiness and performance of the public and private sectors are observed: first-line ACT availability and distribution was widespread, and malaria

diagnosis was commonplace—particularly in the public sector. However, the data also highlight key gaps across both sectors that must be addressed and which are discussed further in this section.

Public sector readiness to test and treat for malaria

Readiness to appropriately manage malaria cases, measured through availability of malaria blood testing and a first-line ACT, was observed at only approximately two-thirds of public health facilities, indicating that around one in three public health facilities were lacking the capacity to both diagnose and appropriately

Table 5 Percent of private sector outlets who reportedly received government or non-governmental support, and among outlets who received a support strategy, type of support received

| | Private for-profit health facility % (95% CI) | Pharmacy % (95% CI) | Drug store % (95% CI) | General retailer % (95% CI) | Itinerant drug vendor % (95% CI) | All private sector % (95% CI) |
|---|--|------------------------|--------------------------|--------------------------------|-------------------------------------|----------------------------------|
| | N = 326 | N = 99 | N = 46 | N = 39 | N = 235 | N = 745 |
| Received any type of support | 60.2 (53.6, 66.4) | 71.7 (61.7, 80.0) | 45.5 (29.7, 62.2) | 3.2 (0.7, 13.8) | 25.5 (18.8, 33.6) | 44.4 (39.0, 49.9) |
| Among outlets with support | N = 196 | N = 69 | N = 19 | N = 1 | N = 64 | N = 349 |
| Report access to subsidized anti-malarials | 58.3 (49.2, 66.9) | 69.4 (58.7, 78.5) | 26.8 (13.3, 46.6) | 0.0 (-) | 55.7 (44.4, 66.5) | 57.5 (51.1, 63.7) |
| Report access to subsidized RDT | 63.5 (54.0, 72.1) | 69.1 (58.9, 77.7) | 60.2 (36.4, 80.0) | 0.0 (-) | 58.6 (45.5, 70.7) | 63.0 (55.9, 69.6) |
| Report received training in the past year on malaria diagnosis (RDT and/or microscopy) and/or the National treatment guidelines for malaria | 65.3 (57.1, 72.7) | 66.0 (53.2, 76.8) | 36.1 (18.0, 59.2) | 100.0 (-) | 42.6 (31.5, 54.4) | 59.1 (53.9, 64.2) |
| Report receiving a supervisory or regulatory visit within the past year | 27.6 (21.7, 34.3) | 17.8 (8.9, 32.6) | 20.7 (5.5, 54.0) | 0.0 (-) | 8.6 (3.9, 18.0) | 21.4 (16.7, 27.0) |
| Report keeping and reporting malaria caseload data to government or non-government organization | 50.3 (40.0, 60.6) | 22.2 (11.8, 37.9) | 18.0 (4.0, 53.4) | 0.0 (-) | 21.1 (11.7, 35.0) | 36.9 (27.8, 47.1) |




Fig. 3 Key indicators by private sector support status




Fig. 4 Median consumer prices for adult RDT and DHA PPQ, by private sector support status

treat uncomplicated malaria. According to Cambodia's national treatment guidelines for malaria, and in order to achieve the universal coverage strategy described in the MEAF, all of the public sector outlet types must be equipped to test for and treat uncomplicated malaria. Moving forward, it will be critical to maintain a constant supply of malaria commodities. At the time of this survey, the CNM was developing the Logistic Management Information System (LMIS) to measure quantification, long-lasting insecticide-treated net (LLIN) demand, forecasting, and stock, with the aim of providing more regular reports and thus reducing the frequency of stock outs in the public sector [14]. The LMIS is expected to ideally move the country towards universal coverage by ensuring a constant supply of malaria commodities at all public sector outlets. Indeed, findings from other countries have supported this prediction, demonstrating that investments to strengthen management information systems can lend a more streamlined, demand-driven, and accountable procurement and supply chain system [15].

The role of the private sector

The majority of private sector outlets screened were not in the business of stocking malaria commodities, with fewer than one in three private for-profit health facilities and one in five pharmacies stocking an anti-malarial. This reflects an overall decline in anti-malarial availability among these private sector outlets in recent years [5]. In 2015, malaria case management services in the private sector were concentrated among private for-profit health facilities and pharmacies, which are the only private sector outlet types authorized to distribute anti-malarial medicines [1]. The concentration of malaria commodities among authorized outlet types may

reflect increased regulation of the private sector and/or may also be a result of a decline in provider incentives to stock anti-malarials, given declining burden and perhaps less consumer demand for malaria treatment. However, the relatively low availability of malaria commodities in the private sector indicates that a febrile patient seeking care in the private sector may have to approach multiple facilities to find one with malaria testing and treatment. This points to the importance of a referral system, such as the Private Sector SMS Referral System piloted in 2012 by the CNM and partners [16], as well as a need to scale up health services at the community level.

While most private sector outlets were not in the business of malaria case management, results nonetheless show that the private sector was responsible for the majority of anti-malarial distribution and malaria testing provision. This finding is consistent with other research in Cambodia and neighboring countries such as Lao PDR and Myanmar [17, 18]. Market share data also illustrate that, while a large portion of the private sector case management was channeled through private for-profit health facilities and pharmacies, there was also a significant contribution from itinerant drug vendors—an illicit and unregulated outlet type in Cambodia. Although itinerant drug vendors are not a formal or regulated outlet type, provider demographic results show that approximately one in five itinerant drug vendors reported having completed university or college, and nearly two in three itinerant drug vendors reported having a health qualification, mostly as a nurse or nursing officer. This suggests that these providers could be considered assets in improving appropriate malaria case management coverage, if they can be appropriately regulated and supervised.

The MEAF has outlined plans to target certain unlicensed providers and encourage them to obtain a licence in order to join the PPM programme, and it also describes goals to enforce existing laws that would prohibit operation of itinerant drug vendors. However, there may be some benefit from further exploration into whether itinerant drug vendors could be effectively licensed and regulated under the PPM programme. Several studies have documented success with the VMW programme [5, 19], which has increased access to appropriate malaria case management in many rural areas of Cambodia utilizing people with overall less education and fewer baseline health qualifications compared to itinerant drug vendors (Additional file 1). In sub-Saharan Africa, several malaria-endemic countries have documented improvements in provider knowledge and performance after implementation of strategies such as training and capacity-building, demand generation, quality assurance, and creating an enabling environment, all of which targeted the informal private sector, including itinerant drug vendors [20]. Furthermore, the WHO has recommended the engagement of itinerant drug vendors, where appropriate, as a method of improving home-based management of malaria [21, 22], and analyses by the U.S. Agency for International Development (USAID) have also concluded that policies through which national programmes engage with private providers—both formal and informal—can be beneficial to improving provision of care for malaria and other important health issues in developing countries [23]. Extending permission to test for and treat malaria to trained and supervised itinerant drug vendors may be an important strategy in Cambodia to accelerate universal coverage of confirmatory testing and appropriate malaria treatment and to continue expanding coverage to remote, rural populations.

Private sector readiness and performance

Where anti-malarials were available in the private sector, the majority of anti-malarial stocking outlets had a first-line ACT available. However, nearly one in three private sector outlets were not stocking a first-line ACT and were primarily stocking chloroquine, which is no longer indicated for use in the national treatment guidelines for malaria. While the majority of anti-malarial-stocking private sector outlets had malaria diagnostic testing available, approximately one in three did not have testing available. These gaps in private sector readiness are a threat to appropriate management of suspected malaria cases, as they demonstrate a potential for presumptive anti-malarial treatment and/or treatment with medicines that are not indicated in the national treatment guidelines for malaria.

Most anti-malarials distributed by the private sector were DHA PPQ, a first-line ACT. However, chloroquine and artemisinin–piperaquine were also distributed in the private sector, indicating that some private sector providers were not in full alignment with the national treatment guidelines for malaria. Indeed, availability data show that all private sector outlet types were found to be stocking chloroquine, with the highest availability observed among general retailers. While availability and market share of a first-line treatment were high among private for-profit health facilities and pharmacies, chloroquine stubbornly persists and most notably among itinerant drug vendors, pointing to the need to completely remove this anti-malarial from the market. One strategy by which to achieve this goal would be to ban the import and sale of this anti-malarial, especially given evidence that a similar ban on oral artemisinin monotherapy in 2008 was found to be a successful measure to remove this anti-malarial from the market [5]. This is also addressed in the MEAF strategy, which stipulates that there will be increased efforts to ban the import and sale of anti-malarial drugs not in national treatment guidelines for malaria.

Private sector support

Results from this study showed that access to any supportive intervention—including subsidized anti-malarials or RDT, training, supervisory or regulatory visits, or reporting caseload data—was associated with higher availability of a first-line ACT, higher availability of malaria testing, higher provider knowledge of first-line treatment guidelines for malaria, and lower availability of an anti-malarial not in the national treatment guidelines for malaria. In addition, the study showed that private sector outlets with access to any supportive intervention priced their malaria commodities lower than outlets that did not have access to any supportive intervention, meaning more affordable access to malaria testing and treatment for consumers.

These results suggest that strategies such as subsidies, training, and supervision can improve private sector readiness and performance, as has been demonstrated in other contexts [24]. However, this study was not designed to evaluate specific types of private sector support, nor was it able to compare the performance of PPM outlets with non-PPM outlets. There is further need to examine the outcomes associated with the various aspects of the PPM programme to identify where there may be a need to strengthen specific components. The extent to which the measures of access to supportive interventions, as outlined in this paper, can be used to inform specific strategies relating to the PPM programme is limited.

Results from this study reflect positively on the work that has been done to-date in Cambodia to engage the private sector. However, there is a need to increase coverage of private sector support and, in doing so, more evidence about the performance of current strategies is needed in order to facilitate efficient and effective progress in the private sector. As intended under the PPM programme, current strategies appear to be reaching private health facilities and pharmacies to a much greater extent than itinerant drug vendors. As noted above, extending private sector support to itinerant drug vendors may be an important strategy for improving overall private sector readiness and performance. In addition, investigation into the merits of other types of private sector strategies, such as integration of RDT financial incentives and information, education, and counseling, may be useful interventions as evidenced among the informal private sector in neighboring Myanmar [25]. Finally, future research that specifically addresses the PPM programme may be merited in order to better understand how this strategy has affected anti-malarial and diagnostic market performance to date and in order to more specifically inform policy decisions relating to this programme.

Gaps in availability of ASMQ FDC and primaquine

In its continuing effort to keep one step ahead of drug resistance, Cambodia's national treatment guidelines for malaria changed in 2014 in response to emerging resistance to DHA PPQ, such that ASMQ FDC is now recommended in geographic areas with DHQ PPQ failure. As of June 2015, failure rates of DHA PPQ have reached over 60% in certain areas of the country, pointing to the immediate need to ensure access to ASMQ FDC [1]. During data collection for this survey, which took place in August and September of 2015, ASMQ FDC was not found. The absence of this anti-malarial in the market may be due in part to a variety of challenges with manufacturing and procurement. Cambodia has faced procurement challenges in the past, most notably after the switch in malaria treatment guidelines to DHA PPQ in 2010, when a lack of suitable manufacturers led to a significant delay and subsequent stock out of first-line anti-malarials in both the public and private sectors [5]. In light of the constantly changing epidemiology of malaria in Cambodia and the Greater Mekong Subregion (GMS) as a whole, it is important that the country is able to respond quickly to changing treatment recommendations and thus avoid lags in the stocking of appropriate treatments. One option to consider are parallel procurement systems whereby two or more types of anti-malarial are stocked in-country to guarantee the availability of an appropriate anti-malarial depending on the drug

resistance, while accepting that drug wastage will be an inevitable reality in the drive toward elimination [5]. Other considerations may include investment into a centralized procurement system, with trained personnel, storage capacity, infrastructure and IT enablement in order to forecast stock and supply, and distribution of sufficient quantities of anti-malarials with minimal delays [26]. In addition, any identification of treatment failure should signal the need to start immediately forecasting sufficient stock for new first-line treatments.

The MEAF and the national treatment guidelines for malaria stipulate the use of primaquine to prevent *P. falciparum* transmission and *P. vivax* relapse, indicating that it should be provided along with a first-line ACT for both types of malaria. This study found that primaquine was universally unavailable at the time of the survey. This may reflect hesitancy to operationalize the use of primaquine without a feasible way to test first for G6PD deficiency [27]. However, WHO recommendations and supporting publications demonstrate that a low dose of primaquine can be safely administered regardless of G6PD status [28–30]. As Cambodia scales up access to primaquine, approaches used in neighboring countries such as Myanmar, Thailand, and Vietnam may be useful to consider, as governments have limited the use of primaquine to facilities that are equipped to either test and/or monitor for signs of G6PD deficiency. However, it should be noted that outlet survey evidence from Myanmar and Thailand illustrates that primaquine availability in these facilities was generally lower compared to other first-line treatments for uncomplicated malaria [31]. This suggests that there may be issues in maintaining constant supply or may demonstrate concerns by the governments that facilities are not adequately equipped to either test and/or monitor for signs of G6PD deficiency. Building on evidence from other countries that have historically included and implemented the use of primaquine in their treatment policy will be helpful to facilitate full implementation of the national treatment guidelines for malaria in Cambodia.

Limitations

Despite its many strengths, the ACTwatch outlet survey has several limitations which have been described in detail elsewhere [8, 32]. Notably, the survey had a cross sectional design, which limits the conclusions that can be drawn about causality as it relates to access to supportive interventions and performance indicators in the private sector. It is also acknowledged that, due to increased regulation of the private sector, especially as it relates to the stocking of oral artemisinin monotherapy, providers may have a disincentive to accurately report certain information, such as the stocking of artemisinin monotherapy or

the stocking of any malaria commodities in outlets which were unlicensed.

Conclusions

As Cambodia steps into an era of malaria elimination, evidence on the availability and distribution of first-line treatment for malaria and malaria diagnostic testing in the public and private sectors is critical. Evidence from the last ACTwatch outlet survey implemented in 2015 illustrates that there is a strong foundation for meeting national malaria elimination goals: first-line ACT availability and distribution was widespread, and malaria diagnosis was commonplace—particularly in the public sector. This evidence can serve as a benchmark for guiding the implementation of strategies outlined in the MEAF as well as other regional initiatives to address elimination activities. The private sector remains responsible for the majority of malaria testing and treatment in Cambodia, indicating that strategies to effectively support the private sector are critical to continued progress. Identifying other regulatory strategies or supportive interventions to address anti-malarial availability and distribution by unauthorized itinerant drug vendors is needed.

Additional file

Additional file 1. Demographic information of private sector providers, by outlet type.

Abbreviations

ACT: artemisinin-based combination therapy; AETD: adult equivalent treatment dose; ASMQ: artesunate–mefloquine; CHW: community health worker; CNM: Cambodia's National Centre for Parasitology, Entomology and Malaria Control; DEF: Department of Food and Drug; DHA PPQ: dihydroartemisinin-piperaquine; FDC: fixed-dose combination; GMS: Greater Mekong Sub-region; G6PD: glucose-6-phosphate dehydrogenase; IV: intravenous; IM: intramuscular; LLIN: long-lasting insecticide-treated net; LMIS: logistic management information system; MEAF: Malaria Elimination Action Framework; MOH: Ministry of Health; OD: operational districts; RDT: rapid diagnostic test; PPM: public private sector mix; PPS: probability proportional to size; PSI: Population Services International; USAID: U. S. Agency for International Development; VMW: village malaria worker; WHO: World Health Organization.

Authors' contributions

The manuscript was conceived and drafted by members of the ACTwatch Group: Anna Fulton, Kathryn A. O'Connell, and Megan Littrell. Data cleaning and analysis were completed by members of the ACTwatch Group: Kevin Duff, Katia Bruxvoort, Julianna Smith, and Anna Fulton. SP and LD contributed to interpretation of the data and findings. All authors read and approved the final manuscript.

Author details

¹ Population Services International, 1120 19th St NW, Suite 600, Washington, DC 20036, USA. ² PSI Cambodia (PSK), No. 29, Street 334, Boeung Keng Kang I, Chamcar Mon, Phnom Penh, Kingdom of Cambodia. ³ The National Centre for Parasitology, Entomology and Malaria Control, 477 Betong Street (Corner St. 92), Village Trapangsvay, Sanakat Phnom Penh Thmey, Khan Sen Sok, Phnom Penh, Kingdom of Cambodia. ⁴ School of Public Health, National Institute of Public Health, Phnom Penh, Kingdom of Cambodia.

Acknowledgements

The authors are grateful to country teams in Cambodia and staff at PSK who helped with the survey, including Mean Phou, Pisidh Voe, Abigail Pratt, Dianna Long and Claire Stokes. The authors would also like to thank the study participants for their time and participation. The authors are also grateful to Dr. Sovannaroth Siv and Dr. Rekol Huy at the Cambodia National Centre for Entomology, Parasitology and Malaria Control for their support during the survey implementation.

ACTwatch Group 2008–2017

Dr. Louis Akulayi; Angela Alum; Andrew Andrada; Julie Archer; Ekundayo D. Arogundade; Erick Auko; Abdul R. Badru; Dr. Katie Bates; Dr. Paul Bouanchaud; Meghan Bruce; Katia Bruxvoort; Peter Buyungo; Angela Camilleri; Dr. Emily D. Carter; Dr. Steven Chapman; Nikki Charman; Dr. Desmond Chavasse; Robyn Cyr; Kevin Duff; Gylsain Guedegbe; Keith Esch; Illah Evance; Anna Fulton; Hellen Gataaka; Tarryn Haslam; Emily Harris; Christine Hong; Catharine Hurley; Whitney Isenhower; Enid Kaabunga; Baraka D Kaaya; Esther Kabui; Dr. Beth Kangwana; Lason Kapata; Henry Kaula; Gloria Kigo; Irene Kyomuhangi; Aliza Lailari; Sandra LeFevre; Dr. Megan Littrell (Principal Investigator, 2014–2017); Greta Martin; Daniel Michael; Erik Monroe; Godefroid Mpanya; Felton Mpasela; Felix Mulama; Dr. Anne Musuva; Julius Ngigi; Edward Ngoma; Marjorie Norman; Bernard Nyauchi; Dr. Kathryn A. O'Connell (Principal Investigator, 2008–2012); Carolyn Ochieng; Edna Ogada; Linda Ongwenyi; Ricki Orford; Saysana Phanalasy; Stephen Poyer; Dr. Justin Rahariniaina; Jacky Raharinjatovo; Lanto Razafindralambo; Solofo Razakamiadana; Christina Riley; Dr. John Rodgers; Dr. Andria Rusk; Tanya Shewchuk; Simon Sensalire; Julianna Smith; Phok Sochea; Tsione Solomon; Raymond Sudo; Martine Esther Tassiba; Katherine Thanel; Rachel Thompson; Mitsuru Toda; Chinazo Ujuju; Marie-Alix Valensi; Dr. Vamsi Vasireddy (Principal Investigator, 2013); Cynthia B. Whitman; Cyprien Zinsou.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

ACTwatch data are made publically available to any interested party. To request a dataset please contact the project Principal Investigator to receive to complete a data request form and further instructions to access ACTwatch data (mlittrell@psi.org or info@psi.org). Please specify in the title of your email 'ACTwatch data request'.

The datasets generated during and/or analysed during the current study are available in the figshare repository <https://doi.org/10.6084/m9.figshare.4892624>.

Ethics approval and consent to participate

The outlet survey protocol received ethical approval from the National Ethics Committee for Health Research in Cambodia and from the Ethical Review Board at PSI (37.2015). Provider interviews and product audits were completed only after administration of a standard informed consent form and provider consent to participate in the study. Providers had the option to end the interview at any point during the study. Standard measures were employed to maintain provider confidentiality and anonymity.

Funding

The Cambodia 2015 ACTwatch outlet survey and the production of this manuscripts received financial support from the Bill and Melinda Gates Foundation.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 5 December 2016 Accepted: 7 April 2017

Published online: 25 April 2017

References

1. CNM. Malaria elimination action framework 2016–2020. PhnomPenh: Malaria Eradication Scientific Alliance Website; 2016. <http://www.malariaeradication.org/knowledge-hub/cambodia-malaria-elimination-action-framework-2016-2020>. Accessed 29 Mar 2017.

2. WHO. World Malaria Report. Geneva: World Health Organization; 2016. World Health Organization Website. <http://www.who.int/malaria/publications/world-malaria-report-2016/report/en/>. Accessed 3 April 2017. .
3. CNM. Annual Malaria Report 2016.
4. Littrell M, Gatakaa H, Phok S, Allen H, Yeung S, Chuor CM, et al. Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys. *Malar J*. 2011;10:328.
5. ACTwatch Group, Novotny J, Singh A, Dyssoley L, Sovannaroth S, Rekol H. Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys. *Malar J*. 2016;15:194.
6. Yeung S, Patouillard E, Allen H, Socheat D. Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. *Malar J*. 2011;10:243.
7. Sokea V. Important regulatory steps being taken in Cambodia to phase out oral artemisinin-based monotherapies. World Health Organization Website. 2010. http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/PL6-3.pdf. Accessed 2 April 2017 .
8. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, et al. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. *Malar J*. 2011;10:326.
9. Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D. The ACTwatch project: methods to describe anti-malarial markets in seven countries. *Malar J*. 2011;10:325.
10. WHO/GMP. Status Report on Artemisinin and ACT Resistance. Geneva: World Health Organization; 2015. World Health Organization Website. <http://apps.who.int/iris/bitstream/10665/250294/1/WHO-HTM-GMP-2016.11-eng.pdf>. Accessed 28 Mar 2017.
11. WHO. Development of a strategy towards elimination of *Plasmodium falciparum* parasites with altered response to artemisinins. Bangkok: Report of an informal consultation; 2008. Malaria Consortium Website. [http://www.malariaconsortium.org/userfiles/file/Resistance-Resources/Summary%20of%20Migrants%20Workshop%20\(8-10%20June%202009\).pdf](http://www.malariaconsortium.org/userfiles/file/Resistance-Resources/Summary%20of%20Migrants%20Workshop%20(8-10%20June%202009).pdf). Accessed 28 Mar 2017.
12. WHO. Emergency response to artemisinin resistance in the Greater Mekong subregion: regional framework for action 2013–2015. Geneva: World Health Organization; 2013. World Health Organization Website. http://apps.who.int/iris/bitstream/10665/79940/1/9789241505321_eng.pdf. Accessed 28 Mar 2017.
13. WHO. Guidelines for the treatment of malaria. 3rd edn. Geneva: World Health Organization; 2015. World Health Organization Website. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf. Accessed 28 Mar 2017.
14. USAID-PMI. President's Malaria Initiative, Greater Mekong Sub-region, Malaria Operational Plan FY 2016. Washington, DC, USA, 2016. Presidents Malaria Initiative. <https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy16/fy-2016-greater-mekong-subregion-malaria-operational-plan.pdf?sfvrsn=4>. Accessed 28 Mar 2017.
15. Mikkelsen-Lopez I, Shango W, Barrington J, Ziegler R, Smith T, deSavigny D. The challenge to avoid anti-malarial medicine stock-outs in an era of funding partners: the case of Tanzania. *Malar J*. 2014;13:181.
16. Malaria Consortium. Project Brief: Private sector SMS referral system pilot. London: Malaria Consortium Website; 2013. <http://www.malariaconsortium.org/media-downloads/229/Private%20sector%20SMS%20referral%20system%20pilot>. Accessed 28 Mar 2017.
17. Khin HS, Aung T, Thi A, White C, ACTwatch Group. Oral artemisinin monotherapy removal from the private sector in Eastern Myanmar between 2012 and 2014. *Malar J*. 2016;15:286.
18. ACTwatch Group. ACTwatch Study Reference Document: Lao PDR Outlet Survey 2015. Washington, DC. 2016. ACTwatch Group Website. <http://www.actwatch.info/sites/default/files/content/publications/attachments/Laos%202015%20Reference%20Document.pdf>. Accessed 28 Mar 2017.
19. Yasuoka J, Poudel KC, Poudel-Tandukar K, Nguon C, Ly P, Socheat D, et al. Assessing the quality of service of village malaria workers to strengthen community-based malaria control in Cambodia. *Malar J*. 2010;9:109.
20. Goodman C, Brieger W, Unwin A, Mills A, Meek S, Greer G. Medicine sellers and malaria treatment in sub-Saharan Africa: what do they do and how can their practice be improved? *Am J Trop Med Hyg*. 2007;77(6 Suppl):203–18.
21. WHO. Scaling up home-based management of malaria: from research to implementation. Geneva: World Health Organization; 2004. World Health Organization Website. http://apps.who.int/iris/bitstream/10665/42918/1/WHO-HTM_MAL_2004.1096.pdf. Accessed 29 Mar 2017.
22. WHO. The Roll Back Malaria strategy for improving access to treatment through home management. Geneva: World Health Organization; 2005. World Health Organization Website. http://apps.who.int/iris/bitstream/10665/69057/1/WHO-HTM_MAL_2005.1101.pdf. Accessed 29 Mar 2017.
23. USAID. National strategy for utilizing the potential of private practitioners in child survival. Washington, DC, 2002. United States Agency for International Development. http://pdf.usaid.gov/pdf_docs/Pnacp202.pdf. Accessed 29 Mar 2017.
24. Tougher S, ACTwatch Group, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, Goodman C, et al. Effect of the Affordable Medicines Facility-malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. *Lancet*. 2012;380:1916–26.
25. Aung T, White C, Montagu D, McFarland W, Hlaing T, Khin HS, et al. Improving uptake and use of malaria rapid diagnostic tests in the context of artemisinin drug resistance containment in eastern Myanmar: an evaluation of incentive schemes among informal private healthcare providers. *Malar J*. 2015;14:105.
26. Sharma S, Chaudhury RR. Improving availability and accessibility of medicines: a tool for increasing healthcare coverage. *Arch Med*. 2015;5:12.
27. Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. *Malar J*. 2015;14:377.
28. WHO. Policy brief on single-dose primaquine as a gametocytocide in *Plasmodium falciparum* malaria. Geneva: World Health Organization; 2005. World Health Organization Website. http://www.who.int/malaria/publications/atoz/who_htm_gmp_2015.1.pdf. Accessed 29 Mar 2017.
29. Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, Gornsawun G, et al. Single low dose primaquine (0.25 mg/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. *PLoS ONE*. 2016;11:e0151898.
30. Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of primaquine in addition to standard artemether–lumefantrine regimen for treatment of acute uncomplicated *Plasmodium falciparum* malaria in Tanzania. *Malar J*. 2016;15:316.
31. ACTwatch Group. Malaria Market Trends in Sub-Saharan Africa: 2009–2014. Washington, D.C. 2016. ACTwatch Group Website. http://www.actwatch.info/sites/default/files/content/publications/attachments/SSA%20Brief_FINAL_NO_BLEEDS.pdf. Accessed 3 April 2017.
32. O'Connell KA, Poyer S, Solomon T, Munroe E, Patouillard E, Njogu J, et al. Methods for implementing a medicine outlet survey: lessons from the anti-malarial market. *Malar J*. 2013;12:52.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

